| Health / Medical Topics |
G250 Peptide Vaccine
A cancer vaccine containing of a synthetic form of the renal cell carcinoma (RCC)-associated antigen G250 with potential antineoplastic activity. Vaccination with G250 peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for the G250 antigen, resulting in decreased tumor growth. Found in the majority of renal cell carcinomas, G250 is a cell surface tumor-associated antigen (TAA) that contains an HLA-A2.1-restricted epitope that is recognized by CTLs. (NCI Thesaurus)
YOU MAY ALSO LIKE
A neuroattenuated, replication-competent, recombinant herpes simplex virus-1 (HSV-1) with potential oncolytic activity. Upon intracerebral administration, oncolytic HSV-1 G207 preferentially replicates within glioma…
G2/mitotic-specific cyclin-B2 (398 aa, ~45 kDa) is encoded by the human CCNB2 gene. This protein plays a role in the regulation of…
G2/mitotic-specific cyclin-B1 (433 aa, ~48 kDa) is encoded by the human CCNB1 gene. This protein plays a role in mediating the progression…
The G2/M DNA damage checkpoint prevents the cell from entering mitosis (M phase) if the genome is damaged. The Cdc2-cyclin B kinase…
Progression from G2 phase to M phase of the standard mitotic cell cycle. (From Gene Ontology)
Phase of the cell cycle following DNA synthesis and preceding mitosis (Gap 2 phase). The chromosomes are tetraploid in this phase. …
